Front Matter

Total Page：16

File Type：pdf, Size：1020Kb

Volume 321 ■ Number 1 ■ April 2007 ■ ISSN 0022-3565 The Journal of PHARMACOLOGY And Experimental Therapeutics A Publication of the American Society for Pharmacology and Experimental Therapeutics Edited for the Society by Rick G. Schnellmann Pharmacology Journals from Nature Publishing Group The newest addition to the Nature Publishing Group portfolio, this journal focuses on primary investigations in pharmacology and pharmacy as well as the most exciting advances in drug discovery, development, regulation and utilization. The offi cial journal of the American Society for Clinical Pharmacology and Therapeutics www.nature.com/cpt 9/193 Pharmacology and Pharmacy 2005 impact factor 7.526* The Pharmacogenomics Journal publishes original research on basic pharmacogenomics research and its clinical applications. Key areas of coverage include the effects of genetic variability on drug toxicity and effi cacy, characterization of polymorphisms relevant to drug action, identifi cation of novel genomic targets for drug development, and potential benefi ts of pharmacogenomics. www.nature.com/tpj 31/124 Genetics and Heredity | 29/193 Pharmacology and Pharmacy 2005 impact factor 3.989* Celebrating its 20th year in publication. Neuropsychopharmacology advances the understanding of the brain and behavior with a focus on molecular, cellular, physiological and psychiatric properties of agents and the identifi cation of new molecular targets for drug development. The offi cial journal of the American College of Neuropsychopharmacology www.neuropsychopharmacology.org 5/94 Psychiatry | 19/200 Neuroscience | 14/193 Pharmacology and Pharmacy 2005 impact factor 5.369* *Journal Citation Reports, Thompson, 2006 No more frequent injections, since In use for over 30 years, and in over ALZET® Osmotic Pumps provide 10,000 published references, implantable continuous delivery for up to 4 weeks. ALZET Osmotic Pumps have a proven These small, implantable infusion pumps history of creating better science. allow you to predictably sustain com- pounds at therapeutic levels, avoiding potentially toxic or misleading side Learn about delivery at constant rates effects. With sizes small enough for by visiting www.alzet.com. mice or even young rats, and large enough for primates or livestock, these pumps also come in a variety of release rates. www.alzet.com '%%+9JG:8I8dgedgVi^dc#6AO:I^hVigVYZbVg`d[9JG:8I8dgedgVi^dc#.

Copy Link

Recommended publications

The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus Lee A
The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus Lee A. Dawson, Ph.D., Huy Q. Nguyen, B.S., and Ping Li, B.S. Preclinical evidence has suggested a possible role for the 5-HT6 increases in extracellular glutamate levels in both frontal receptor in the treatment of cognitive dysfunction. However, cortex and dorsal hippocampus, respectively. These effects were currently there is little neurochemical evidence suggesting the completely attenuated by infusion of tetrodotoxin but mechanism(s) which may be involved. Using the selective unaffected by the muscarinic antagonist, atropine. Here we 5-HT6 antagonist SB-271046 and in vivo microdialysis, we demonstrate for the first time the selective enhancement of have evaluated the effects of this compound on the modulation excitatory neurotransmission by SB-271046 in those brain of basal neurotransmitter release within multiple brain regions regions implicated in cognitive and memory function, and of the freely moving rat. SB-271046 produced no change in provide mechanistic evidence in support of a possible basal levels of dopamine (DA), norepinephrine (NE) or 5-HT therapeutic role for 5-HT6 receptor antagonists in the in the striatum, frontal cortex, dorsal hippocampus or nucleus treatment of cognitive and memory dysfunction. accumbens. Similarly, this compound had no effect on [Neuropsychopharmacology 25:662–668, 2001] excitatory neurotransmission in the striatum or nucleus © 2001 American College of Neuropsychopharmacology. accumbens. Conversely, SB-271046 produced 3- and 2-fold Published by Elsevier Science Inc. KEY WORDS: 5-HT6 receptor; SB-271046; Microdialysis; sma et al. 1993; Ruat et al.
[Show full text]
M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Defic
M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Deficits in Sprague–Dawley and Wistar Rats Geoffrey B. Varty, Ph.D., Vaishali P. Bakshi, Ph.D., and Mark A. Geyer, Ph.D. a In a recent study using Wistar rats, the serotonergic 5-HT2 1 receptor agonist cirazoline disrupts PPI. As risperidone a receptor antagonists ketanserin and risperidone reduced the and M100907 have affinity at the 1 receptor, a final study disruptive effects of the noncompetitive N-methyl-D- examined whether M100907 would block the effects of aspartate (NMDA) antagonist dizocilpine on prepulse cirazoline on PPI. Risperidone partially, but inhibition (PPI), suggesting that there is an interaction nonsignificantly, reduced the effects of dizocilpine in Wistar between serotonin and glutamate in the modulation of PPI. rats, although this effect was smaller than previously In contrast, studies using the noncompetitive NMDA reported. Consistent with previous studies, risperidone did antagonist phencyclidine (PCP) in Sprague–Dawley rats not alter the effects of dizocilpine in Sprague–Dawley rats. found no effect with 5-HT2 antagonists. To test the hypothesis Most importantly, M100907 pretreatment fully blocked the that strain differences might explain the discrepancy in effect of dizocilpine in both strains; whereas SDZ SER 082 these findings, risperidone was tested for its ability to had no effect. M100907 had no influence on PPI by itself reduce the PPI-disruptive effects of dizocilpine in Wistar and did not reduce the effects of cirazoline on PPI. These and Sprague–Dawley rats. Furthermore, to determine studies confirm the suggestion that serotonin and glutamate which serotonergic receptor subtype may mediate this effect, interact in modulating PPI and indicate that the 5-HT2A the 5-HT2A receptor antagonist M100907 (formerly MDL receptor subtype mediates this interaction.
[Show full text]
Early-Life Experience, Epigenetics, and the Developing Brain
Neuropsychopharmacology REVIEWS (2015) 40, 141–153 & 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 REVIEW ............................................................................................................................................................... www.neuropsychopharmacologyreviews.org 141 Early-Life Experience, Epigenetics, and the Developing Brain 1 ,1 Marija Kundakovic and Frances A Champagne* 1Department of Psychology, Columbia University, New York, NY, USA Development is a dynamic process that involves interplay between genes and the environment. In mammals, the quality of the postnatal environment is shaped by parent–offspring interactions that promote growth and survival and can lead to divergent developmental trajectories with implications for later-life neurobiological and behavioral characteristics. Emerging evidence suggests that epigenetic factors (ie, DNA methylation, posttranslational histone modifications, and small non- coding RNAs) may have a critical role in these parental care effects. Although this evidence is drawn primarily from rodent studies, there is increasing support for these effects in humans. Through these molecular mechanisms, variation in risk of psychopathology may emerge, particularly as a consequence of early-life neglect and abuse. Here we will highlight evidence of dynamic epigenetic changes in the developing brain in response to variation in the quality of postnatal parent–offspring interactions. The recruitment of epigenetic pathways for the
[Show full text]
Mechanism of Action of Antidepressants and Mood Stabilizers
79 MECHANISM OF ACTION OF ANTIDEPRESSANTS AND MOOD STABILIZERS ROBERT H. LENOX ALAN FRAZER Bipolar disorder (BPD), the province of mood stabilizers, the more recent understanding that antidepressants share has long been considered a recurrent disorder. For more this property in UPD have focused research on long-term than 50 years, lithium, the prototypal mood stabilizer, has events, such as alterations in gene expression and neuroplas- been known to be effective not only in acute mania but ticity, that may play a significant role in stabilizing the clini- also in the prophylaxis of recurrent episodes of mania and cal course of an illness. In our view, behavioral improvement depression. By contrast, the preponderance of past research and stabilization stem from the acute pharmacologic effects in depression has focused on the major depressive episode of antidepressants and mood stabilizers; thus, both the acute and its acute treatment. It is only relatively recently that and longer-term pharmacologic effects of both classes of investigators have begun to address the recurrent nature of drugs are emphasized in this chapter. unipolar disorder (UPD) and the prophylactic use of long- term antidepressant treatment. Thus, it is timely that we address in a single chapter the most promising research rele- vant to the pharmacodynamics of both mood stabilizers and MOOD STABILIZERS antidepressants. As we have outlined in Fig. 79.1, it is possible to charac- The term mood stabilizer within the clinical setting is com- terize both the course and treatment of bipolar and unipolar monly used to refer to a class of drugs that treat BPD.
[Show full text]
Neuropsychopharmacology (2015) 40, 2853–2855 © 2015 American College of Neuropsychopharmacology
Neuropsychopharmacology (2015) 40, 2853–2855 © 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Commentary Neuropsychopharmacology: Reflections on 40 Volumes Alan Frazer*,1 1 Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA Neuropsychopharmacology (2015) 40, 2853–2855; doi:10.1038/npp.2015.290 This issue completes volume 40 of Neuropsychopharmaco- methodology has not followed in concert with pre-clinical logy (NPP), with the first issue published in December, 1987. advances such that most efficacy studies still lump together This should be distinguished from our 40th anniversary; what are heterogeneous groups of patients. One might say for the first several years, issues were thin, months were how can we subdivide in the absence of biomarkers, which skipped, and multiple volumes were published per year. To do not exist? But one might also ask how can we hope to find commemorate this accomplishment, the editor-in-chief a biomarker among a group of patients that might have 3, 7, (Dr Carlezon) asked me as in-coming ACNP President to or 10 different pathologies, all leading to the same behavioral write a brief overview of my views on the developments in output. Talk about the chicken and the egg! our field over this time period, using highly cited articles Another theme that continues into the present is the time- published in NPP as a guide. dependent, downstream consequences of acute actions of Early on, two articles highlight themes that continue today. some type of psychotherapeutic drugs that correlate better One is the development of animal models for psychiatric with optimal clinical improvement.
[Show full text]
Pharmacogenomics: the Promise of Personalized Medicine for CNS Disorders
Neuropsychopharmacology REVIEWS (2009) 34, 159–172 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $30.00 REVIEW ............................................................................................................................................................... www.neuropsychopharmacology.org 159 Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders Jose de Leon*,1,2,3,4 1 2 Mental Health Research Center, Eastern State Hospital, University of Kentucky, Lexington, KY, USA; College of Medicine, 3 4 University of Kentucky, Lexington, KY, USA; College of Pharmacy, University of Kentucky, Lexington, KY, USA; Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, Medical School, University of Granada, Granada, Spain This review focuses first on the concept of pharmacogenomics and its related concepts (biomarkers and personalized prescription). Next, the first generation of five DNA pharmacogenomic tests used in the clinical practice of psychiatry is briefly reviewed. Then the possible involvement of these pharmacogenomic tests in the exploration of early clinical proof of mechanism is described by using two of the tests and one example from the pharmaceutical industry (iloperidone clinical trials). The initial attempts to use other microarray tests (measuring RNA expression) as peripheral biomarkers for CNS disorders are briefly described. Then the challenge of taking pharmacogenomic tests (compared to drugs) into clinical practice is explained by focusing on regulatory
[Show full text]
Before They Called It Psychopharmacology* Heinz E
NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO. 4 291 SPECIAL LECTURE Before They Called It Psychopharmacology* Heinz E. Lehmann, M.D. BEFORE THEY CALLED IT Johns Hopkins, who called the domain of psychophar PSYCHOPHARMACOLOGY macology "certainly very meager." Macht conducted pharmacologic experiments with opium narcotics and It is a great privilege and honor to be here today, giv coal tar analgesics on reaction time, tapping speed, etc., ing the second annual lecture on the history of psy much as Kraepelin as early as 1883 had done in Wundt's chopharmacology. My friend Frank Ayd did such an laboratory with alcohol and caffeine, calling it then Phar admirable job with his lecture last year, on the early macopsychologie (Macht 1920). history, that I have had a hard problem finding gaps W. Freeman, in 1931, wrote a more general paper to fill. What I have finally chosen to do is to trace for in the Journal of the American Medical Association on you some of the early history, complete with anecdotes, what he called psychochemistry, and in 1935 Thorner which preceded our modern notions of psychology and wrote the fIrst paper resembling our modern concept pharmacology and then to tell you something of my of the term with "Psychopharmacology of Sodium own experiences and findings in the psychiatric world Amytal in Catatonia." I will discuss this paper in more of the 1940s and 1950s, a world that was remarkably detail later . After a careful search of the modern litera different and simplistic compared to today. I also in ture, I came to the conclusion that official general use tend to give you a subjective "oral history" of my own of the term psychopharmacology in publications dates stumbling attempts to make some sense out of the only to 1960, following a paper by Ross and Cole enti vague and somewhat chaotic potpourri of ideas and tled "Psychopharmacology," when also psychophar pharmacologic approaches to psychiatric problems a macology appears for the fIrst time as a free-standing half century ago.
[Show full text]
Neuropsychopharmacology - Mirjam A.F.M
PHARMACOLOGY – Vol. I - Neuropsychopharmacology - Mirjam A.F.M. Gerrits and Jan M. van Ree NEUROPSYCHOPHARMACOLOGY Mirjam A.F.M. Gerrits and Jan M. van Ree Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands Keywords: psychopharmacology, neuropharmacology, central nervous system, antipsychotics, schizophrenia, antidepressants, mood stabilizers, anxiolytics, benzodiazepines Contents 1. Introduction 2. Chemical synaptic transmission in the central nervous system 3. Psychopharmacology and psychotropic drugs 4. Antipsychotics 4.1. Schizophrenia 4.2. Etiology and Pathogenesis of Schizophrenia 4.3. Antipsychotic Drugs 4.3.1. Mechanism of Action 4.3.2. Side Effects of Antipsychotics 4.3.3. Novel Targets for Antipsychotic Drug Action 5. Antidepressants and mood stabilizers 5.1. Etiology and Pathogenesis of Affective Disorders 5.2. Antidepressive Drugs and Mood-stabilizers 5.2.1. Monoamine Oxidase Inhibitors 5.2.2. Tricyclic Antidepressants 5.2.3. Selective 5-HT Uptake Inhibitors 5.2.4. Newer, ‘Atypical’ Antidepressant Drugs 5.2.5. Mood-stabilizers 6. Anxiolytics 6.1. Benzodiazepines 6.1.1. Mechanism of Action 6.1.2. Therapeutic and Side Effects 6.1.3. Pharmacokinetic Aspects Acknowledgements GlossaryUNESCO – EOLSS Bibliography Biographical SketchesSAMPLE CHAPTERS Summary Neuropsychopharmacology is a broad and growing field that is related to several disciplines, including neuropharmacology, psychopharmacology and fundamental neuroscience. It comprises research on the action of psychoactive drugs on different levels. This ranges from molecular and biochemical characterization, to behavioral effects in experimental animals, and finally to clinical application. Over the years, the developments in the neuropsychopharmacological field have led to advances in our ©Encyclopedia of Life Support Systems (EOLSS) PHARMACOLOGY – Vol.
[Show full text]
Pharmacogenomic Testing for Selected Conditions Final Evidence Report
Pharmacogenomic testing for selected conditions Final evidence report December 9, 2016 Health Technology Assessment Program (HTA) Washington State Health Care Authority PO Box 42712 Olympia, WA 98504-2712 (360) 725-5126 www.hca.wa.gov/about-hca/health-technology-assessment [email protected] Pharmacogenomic Testing for Selected Conditions A Health Technology Assessment Prepared for Washington State Healthcare Authority FINAL REPORT December 9, 2016 Acknowledgement This report was prepared by: Hayes, Inc. 157 S. Broad Street Suite 200 Lansdale, PA 19446 P: 215.855.0615 F: 215.855.5218 This report is intended to provide research assistance and general information only. It is not intended to be used as the sole basis for determining coverage policy or defining treatment protocols or medical modalities, nor should it be construed as providing medical advice regarding treatment of an individual’s specific case. Any decision regarding claims eligibility or benefits, or acquisition or use of a health technology is solely within the discretion of your organization. Hayes, Inc. assumes no responsibility or liability for such decisions. Hayes employees and contractors do not have material, professional, familial, or financial affiliations that create actual or potential conflicts of interest related to the preparation of this report. WA – Health Technology Assessment December 9, 2016 Table of Contents EVIDENCE SUMMARY ...................................................................................................................................
[Show full text]
Neuropsychopharmacology of JNJ-55308942: Evaluation of a Clinical Candidate Targeting P2X7 Ion Channels in Animal Models of Neuroinflammation and Anhedonia
www.nature.com/npp ARTICLE Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia Anindya Bhattacharya1, Brian Lord1, Jan-Sebastian Grigoleit1, Yingbo He1, Ian Fraser1, Shannon N. Campbell1, Natalie Taylor1, Leah Aluisio1, Jason C. O’Connor2, Mariusz Papp3, Christa Chrovian1, Nicholas Carruthers1, Timothy W. Lovenberg1 and Michael A. Letavic1 Emerging data continues to point towards a relationship between neuroinflammation and neuropsychiatric disorders. ATP-induced activation of P2X7 results in IL-1β release causing neuroinflammation and microglial activation. This study describes the in-vitro and in-vivo neuropharmacology of a novel brain-penetrant P2X7 antagonist, JNJ-55308942, currently in clinical development. JNJ- 55308942 is a high-affinity, selective, brain-penetrant (brain/plasma of 1) P2X7 functional antagonist. In human blood and in mouse blood and microglia, JNJ-55308942 attenuated IL-1β release in a potent and concentration-dependent manner. After oral dosing, the compound exhibited both dose and concentration-dependent occupancy of rat brain P2X7 with an ED50 of 0.07 mg/kg. The P2X7 antagonist (3 mg/kg, oral) blocked Bz-ATP-induced brain IL-1β release in conscious rats, demonstrating functional effects of target engagement in the brain. JNJ-55308942 (30 mg/kg, oral) attenuated LPS-induced microglial activation in mice, assessed at day 2 after a single systemic LPS injection (0.8 mg/kg, i.p.), suggesting a role for P2X7 in microglial activation. In a model of BCG- induced depression, JNJ-55308942 dosed orally (30 mg/kg), reversed the BCG-induced deficits of sucrose preference and social interaction, indicating for the first time a role of P2X7 in the BCG model of depression, probably due to the neuroinflammatory component induced by BCG inoculation.
[Show full text]
Effects of the Kappa-Opioid Receptor Agonist, U69593, on the Development of Sensitization and on the Maintenance of Cocaine Self
Effects of the Kappa-opioid Receptor Agonist, U69593, on the Development of Sensitization and on the Maintenance of Cocaine Self-administration Susan Schenk, Ph.D., Brian Partridge, M.S., and Toni S. Shippenberg, Ph.D. Previous studies showed that prior administration of with each self-administered cocaine infusion for one group kappa-opioid agonists decreased the development of whereas responding of another group was reinforced by a sensitization to some of the behavioral effects of cocaine. The cocaine infusion alone. On the test day, pretreatment with present study sought to determine whether the development U69593 (0.32 mg/kg) decreased responding during each of sensitization to cocaine’s reinforcing effects was also hour of the 10 hr session for the group that was reinforced sensitive to antagonism by kappa-opioid agonists. During a with cocaine plus the cocaine-associated stimulus. U69593 pretreatment phase, the kappa-opioid agonist, U69593 (0.0 failed to produce a long-lasting disruption of cocaine self- or 0.32 mg/kg) was administered prior to (1) 2 daily administration for rats that were trained and tested without injections of cocaine (0.0 or 20.0 mg/kg), or (2) cocaine or the cocaine-associated stimulus. These data suggest that the saline administered via a yoking procedure. Cocaine acquisition and maintenance of cocaine self-administration pretreatment decreased the latency to acquisition of cocaine are differentially sensitive to manipulations of kappa-opioid self-administration. However, prior administration of systems. Further, the disruption of cocaine self- U69593 during the pretreatment phase failed to attenuate administration by U69593 may be due to interactions with the development of this sensitized response to cocaine’s mechanisms that underlie facilitative effects of stimuli that reinforcing effect.
[Show full text]
Thomas A. Ban Documenting the History of CINP
International Network for the History of Neuropsychopharmacology Electronic Archives Individual Collections Thomas A. Ban Documenting the History of CINP Edited by Peter R. Martin International Network for the History of Neuropsychopharmacology Risskov 2015 2 3 Contents PREFACE ..................................................................................................................................................... 4 CHAPTER 1: CINP AND ITS PAST .......................................................................................................... 6 Missing from the Membership Directory: Deceased, Retired, or Dropped? ............................................ 7 CHAPTER 2: HISTORY OF THE CINP .................................................................................................. 12 Historical Background ............................................................................................................................ 13 The Founding of CINP (Milan, May 1957 – Zurich, October 1957) ...................................................... 13 Interaction of Basic Scientists and Clinicians (Rome 1958 – Tarragona 1968) ..................................... 14 Communication of Findings (Prague 1970 – Florence 1984) ................................................................. 15 Communication of Interpretations (San Juan 1986 – Paris 2004) .......................................................... 16 Organizational Changes (Melbourne 1996 – Paris 2004) ......................................................................
[Show full text]